Acute Myeloid Leukemia Pipeline Analysis 2026: Highlights 100+ Companies And 110+ Drug Candidates
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Acute Myeloid Leukemia (AML) - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive global assessment of the Acute Myeloid Leukemia (AML) pipeline, covering more than 100 companies and over 110 investigational therapies. It evaluates clinical and nonclinical candidates by development stage, product type, route of administration and molecule type, while also examining discontinued and inactive programs.
AML is a rapidly progressing myeloid neoplasm characterized by clonal expansion of immature myeloid-derived blasts in peripheral blood and bone marrow. Disease progression can result in ineffective erythropoiesis and megakaryopoiesis, cytopenias and bone marrow failure. AML may also arise following myeloproliferative neoplasms, myelodysplastic syndromes, aplastic anemia and other antecedent hematologic conditions.
Diagnostic evaluation may include peripheral blood and bone marrow assessment, cytogenetic analysis, molecular profiling and laboratory testing for markers associated with high tumor burden and rapid cellular turnover. Risk-adapted AML treatment can incorporate intensive cytotoxic chemotherapy, molecularly targeted agents and hematopoietic stem cell transplantation. Induction therapy is intended to achieve complete remission, followed by consolidation strategies designed to address measurable residual disease and reduce relapse risk.
Acute Myeloid Leukemia Pipeline Scope
The report combines scientific, clinical and commercial analysis of emerging AML therapies. Individual pipeline profiles include mechanism of action, clinical trial activity, regulatory progress and product development milestones. Coverage also extends to collaborations, licensing agreements, mergers and acquisitions, funding, regulatory designations and other strategic developments influencing the Acute Myeloid Leukemia treatment landscape.
Pipeline candidates are assessed across Phase III, Phase II, Phase I, pre-clinical and discovery stages. The analysis also segments products by oral, intravenous, subcutaneous, parenteral and topical routes of administration. Molecule categories include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. Product strategies are classified as monotherapy, combination therapy or candidates being evaluated in both settings.
Selected Emerging Acute Myeloid Leukemia Drugs
- Orca-T - Orca Biosystems, Inc.: An investigational allogeneic T-cell immunotherapy composed of purified regulatory T-cells, hematopoietic stem cells and conventional T-cells from matched related or unrelated donors. Orca-T is in the Preregistration stage for AML and is also being investigated in other hematologic malignancies. Bleximenib - Johnson & Johnson: Also known as JNJ-75276617, bleximenib is an oral small-molecule menin-KMT2A inhibitor targeting AML with KMT2A rearrangements or NPM1 mutations. The candidate is in Phase III development. Romaciclib - Ryvu Therapeutics: A selective CDK8 and CDK19 inhibitor designed to disrupt transcriptional programs associated with cancer cell survival. Romaciclib is being evaluated in Phase II development for AML. ABD-3001 - Advanced BioDesign: A small-molecule inhibitor of ALDH1 and ALDH3 intended to generate metabolic stress and target cancer stem cells. ABD-3001 is in Phase I/II development across AML and other cancers. CER-1236 - CERo Therapeutics Holdings, Inc.: An autologous chimeric engulfment receptor T-cell therapy incorporating TIM-4, Toll-like receptor 2, CD28 and CD3? domains. The Phase I candidate is designed to promote tumor cell phagocytosis, lysis, antigen processing and adaptive immune activation. PRO CAR-301 - Promicell INC.: A preclinical autologous CD33-directed CAR T-cell therapy incorporating the SAVVY/IL-18 armor. The program targets CD33, which is expressed across a substantial proportion of AML cells.
Other products covered include Clifutinib, BL-M11D1, Tagraxofusp, Cusatuzumab, QHRD-107, DFP-10917, MEN1703, Debio-1562M, AK-117, AZD-3632, MB-dNPM1-TCR.1, AB-8939, CTX-712, MP-0533, GDX-012, ARD-103 and GB3226.
Companies Advancing AML Research and Development
The competitive landscape includes Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics and Lomond Therapeutics.
Strategic Insights and Key Questions
The report examines unmet needs, emerging treatment trends, novel technologies and the anticipated impact of investigational therapies on the AML market. It evaluates how many companies and products are active at each stage of development, which candidates have reached mid-stage or late-stage trials and what regulatory designations have been granted.
Additional analysis addresses current AML clinical studies, development status, Industry-Industry and Industry-Academia collaborations, licensing transactions, mergers and acquisitions. These insights support pharmaceutical companies, biotechnology organizations, investors, researchers and other stakeholders seeking to understand competitive positioning and future opportunities within the global Acute Myeloid Leukemia pipeline.
Key Topics Covered:
Introduction
Executive Summary
Acute Myeloid Leukemia (AML): Overview
- Introduction Signs and Symptoms Causes Diagnosis Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
Acute Myeloid Leukemia (AML)- Analytical Perspective
Late Stage Products (Preregistration)
- Comparative Analysis
Orca-T: Orca Biosystems, Inc
- Product Description Research and Development Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Romaciclib: Ryvu Therapeutics
- Product Description Research and Development Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
CER-1236: CERo Therapeutics Holdings, Inc.
- Product Description Research and Development Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
PRO CAR-301: Promicell INC.
- Product Description Research and Development Product Development Activities
Inactive Products
- Comparative Analysis
Acute Myeloid Leukemia (AML) Key Companies
Acute Myeloid Leukemia (AML) Key Products
Acute Myeloid Leukemia (AML)- Unmet Needs
Acute Myeloid Leukemia (AML)- Market Drivers and Barriers
Acute Myeloid Leukemia (AML)- Future Perspectives and Conclusion
Acute Myeloid Leukemia (AML) Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
For more information about this clinical trials report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment